Small Animal Containment

由于嵌合小鼠模型领域的突出进展和重要发展 由人类免疫系统和细胞重组，核心H，小动物生物遏制(ABC)核心 扩大了它的范围，现在包括两个网站。A站点位于马萨诸塞州综合医院 B场地是达纳-法伯癌症研究所(DFCI)现有的BL-3ABC设施。 站点A将提供以下服务： 1.人源化BLT小鼠的产生(NOD-SCID-Hu小鼠移植人胎胸腺、肝脏和 供CFAR研究人员用于实验的造血干细胞(HSC)，将在 该核心的MGH或DFCI站点，或在合作调查员的站点，在转让 BLT小鼠被送到他/她的动物设施。 2.BLT小鼠外周血白细胞出血及流式细胞术分析 在合作研究人员使用之前进行免疫重建。 3.对于选择在MGH现场进行实验的合作调查人员，在 处理和分析感染艾滋病毒的小鼠。 4.对于选择在自己的动物设施中进行实验的合作研究人员，培训 安全处理感染艾滋病毒的小鼠。 5.产生的人类病毒特异性细胞和体液免疫反应的进一步特征 在感染HIV的BLT小鼠中，扩大这种模型可以支持的研究领域。 站点B将提供以下服务： 1.使用防止传染性病原体在动物之间传播的动物设施。 2.在处理可能感染人类或动物的动物方面提供技术支持。 3.获得将HIV-1接种到嵌合BLT或NOG中的技术支持(即， CD34+人HSC重组的NOD/SCID.IL-2RYNull)小鼠，将被安置以评估 候选抗病毒药物在这些新的小动物模型中的有效性和毒性。一个特殊的加分 B站点是允许与结核分枝杆菌(MTB)或HIV-1/MTB混合感染一起工作的能力。 4.使用安全的工作条件。 5.在小动物模型中安全处理潜在的人类病原体的培训。

Due to outstanding progress and important developments in the field of chimeric mouse models reconstituted with human immune systems and cells, Core H, the Small Animal Biocontainment (ABC) Core expanded its scope and now includes two sites. Site A is located at the Massachusetts General Hospital (MGH), and Site B is the existing BL-3 ABC Facility at the Dana-Farber Cancer Institute (DFCI). Site A will provide the following services: 1. Generation of humanized BLT mice (NOD-SCID-Hu mice transplanted wit human fetal thymus, liver and hematopoietic stems cells (HSC)) for CFAR investigators to use for experiments, to be performed at the MGH or DFCI Sites of this core, or at the site of the collaborating investigator, following transfer of the BLT mice to his/her animal facility. 2. Bleeding and flow cytometry of peripheral blood leukocytes of the BLT mice to characterize their human immune reconstitution prior to use by collaborating investigators. 3. For collaborating investigators choosing to perform their experiments at the MGH site, support in the handling and analysis of HIV-infected mice. 4. For collaborating investigators choosing to perform experiments in their own animal facilities, training in the safe handling of HIV-infected mice. 5. Further characterization of the human virus-specific cellular and humoral immune responses generated in HIV-infected BLT mice, to expand the areas of investigation this model can support. Site B will provide the following services: 1. The use of an animal facility in which the spread of contagious agents is prevented between animals. 2. Technical support in handling animals potentially infectious to humans or animals. 3. Access to technical support for performing HIV-1 inoculations into chimeric BLT or NOG (i.e., NOD/SCID.IL-2RYNull) mice reconstituted with CD34+ human HSC, which will be housed to evaluate candidate antiviral agents for efficacy and toxicity in these novel small animal models. A special plus of Site B is the ability to permit work with Mycobacterium tuberculosis (MTb) or HIV-1/MTb co-infections. 4. The use of safe working conditions. 5. Training for safe handling of potential human pathogens in small animal models.